Skip to main content
SpringerLink
Log in

The Role of Induction Therapy for Resectable Non-Small Cell Lung Cancer

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Lung cancer is the leading cause of cancer death among men and women in the US. Surgical resection is potentially curative; however, even after complete resection many patients experience systemic recurrence and subsequently die of their disease. As a means of reducing the chances of recurrence there has been significant interest in combining chemotherapy with surgical resection. Recently, several large phase III clinical trials have demonstrated a significant survival benefit with adjuvant or postoperative cisplatin-based chemotherapy. Use of preoperative or induction chemotherapy has also been an area of active investigation; however, the trials that have demonstrated a survival benefit were small in size, and there has not been widespread acceptance of this treatment approach. The trials of induction chemoradiotherapy have generally been performed in patients with locally advanced disease, frequently in patients with involvement of the level 2 mediastinal lymph nodes (N2). The results of the recent US Intergroup trial, 0139, which compared induction chemoradiotherapy followed by surgical resection versus nonsurgical therapy with chemoradiotherapy in patients with resectable stage IIIA-N2 disease, revealed equivalent overall survival between the two treatment approaches. The results of an unplanned subset analysis of patients who were treated with lobectomy in the surgical arm have generated significant interest and debate. When the strategy of induction therapy is used, pathological clearance of the mediastinal lymph nodes is a significant prognostic factor for overall survival. Current investigations are attempting to determine the optimal method of assessing this critical prognostic factor. The toxicity, efficacy and proper selection of patients for induction therapy, particularly induction chemoradiotherapy, will be assessed in ongoing and future clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106–30

    Article  PubMed  Google Scholar 

  2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24 (28): 4539–44

    Article  PubMed  Google Scholar 

  3. Bulzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102–10

    Article  PubMed  CAS  Google Scholar 

  4. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128: 452–62

    Article  PubMed  Google Scholar 

  5. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001; 121: 472–83

    Article  PubMed  CAS  Google Scholar 

  6. Rendina EA, Venuta F, De Giacomo T, et al. Induction chemotherapy for T4 centrally located non-small cell lung cancer. J Thorac Cardiovasc Surg 1999; 117: 225–33

    Article  PubMed  CAS  Google Scholar 

  7. Albain KS, Rusch K, Crowley J, et al. Long term survival after concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery in bulky, stages IIIA (N2) and IIIB non-small cell lung cancer: 6-year outcomes from Southwest Oncology Group Study 8805 [abstract no. 1801]. 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA). Pro Am Soc Clin Oncol 1999; 19: 467a

    Google Scholar 

  8. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 2005; 23: 3270–8

    Article  PubMed  CAS  Google Scholar 

  9. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111 (6): 1710–7

    Article  PubMed  CAS  Google Scholar 

  10. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899–909

    Article  Google Scholar 

  11. Douillard JY, Rosell R, Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small cell lung cancer (NSCLC) patients: final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association [abstract no. 7013]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL). J Clin Oncol 2005; 23: 624s

    Google Scholar 

  12. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589–97

    Article  PubMed  CAS  Google Scholar 

  13. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351–60

    Article  PubMed  Google Scholar 

  14. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer: report of cancer and leukemia Group B Protocol 9633 [abstract no. LBA7019]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5–8; New Orleans (LA). J Clin Oncol 2004; 22: 621s

  15. Strauss GM, Herndon II JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract no. 7007]. 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA). J Clin Oncol 2006; 24: 365s

    Google Scholar 

  16. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153–8

    Article  PubMed  CAS  Google Scholar 

  17. Slebos RJ, Hruban RH, Dalesio O, et al. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991; 83: 1024–7

    Article  PubMed  CAS  Google Scholar 

  18. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999; 17: 668–75

    PubMed  CAS  Google Scholar 

  19. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323 (9): 561–5

    Article  PubMed  CAS  Google Scholar 

  20. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 2006; 19: 448–57

    Google Scholar 

  21. Camps C, Sirera R, Bremnes R, et al. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer 2005; 50: 339–46

    Article  PubMed  Google Scholar 

  22. Aviel-Ronen S, Blackhall FH, Shepherd FA, et al. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006; 8: 30–8

    Article  PubMed  CAS  Google Scholar 

  23. Pass H, Pogrebniak H, Steinberg S. Randomized trial of neoadjuvant therapy for lung cancer interim analysis. Ann Thorac Surg 1992; 53: 992–8

    Article  PubMed  CAS  Google Scholar 

  24. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21: 1–6

    Article  PubMed  CAS  Google Scholar 

  25. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673–80

    Article  PubMed  CAS  Google Scholar 

  26. DePierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with surgery in resectable stage I (except TINO), II, and IIIA non-small cell lung cancer. J Clin Oncol 2002; 20: 247–53

    Article  PubMed  Google Scholar 

  27. Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003; 125: 254–60

    Article  PubMed  Google Scholar 

  28. Pisters K, Vallieres E, Bunn PA, et al. S9900: a phase III trial of surgery alone or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results [abstract no. 7012]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL). J Clin Oncol 2005: 23: 624s

    Article  Google Scholar 

  29. Mattson KV, Abratt RP, ten Velde G, et al. Docetaxel as neoadjuvant therapy for radically treatable stage III non-smallcell lung cancer: a multinational randomised phase III study. Ann Oncol 2003; 14 (1): 116–22

    Article  PubMed  CAS  Google Scholar 

  30. Pisters K, Ginsberg R, Giroux DJ, et al. Bimodality Lung Oncology Team (BLOT) trial of induction paclitaxel/carboplatin in early stage non-small cell lung cancer (NSCLC): long term follow-up of a phase II trial [abstract 2544]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31–Jun 3; Chicago (IL). Proc Am Soc Clin Oncol 2003; 22: 633

    Google Scholar 

  31. Scagliotti G. Preliminary results of the CHEST: a phase III study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in clinical early stages non-small cell lung cancer (NSCLC) [abstract no. LBA7023]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL). J Clin Oncol 2005; 23: 626s

    Google Scholar 

  32. van Meerbeeck JP, Kramer G, van Schil PE, et al. A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) [abstract no. LBA7015]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL). J Clin Oncol 2005; 23: 624s

    Google Scholar 

  33. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309) [abstract no. 7014]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13–17; Orlando (FL). J Clin Oncol 2005; 23: 624s

    Google Scholar 

  34. Johnstone DW, Byhardt RW, Ettinger D, et al. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54: 365–9

    Article  PubMed  Google Scholar 

  35. Shepherd FA, Johnston MR, Payne D, et al. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Br J Cancer 1998; 78: 683–5

    Article  PubMed  CAS  Google Scholar 

  36. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000; 18: 2981–9

    PubMed  CAS  Google Scholar 

  37. Albain K, Rusch V, Crowley J, et al. Long-term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stage IIIA (N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group Study 8805 [abstract no. 1801]. 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15–18; Atlanta (GA). Proc Am Soc Clin Oncol 1999; 18: 467a

    Google Scholar 

  38. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21: 1752–9

    Article  PubMed  CAS  Google Scholar 

  39. Albain K, Scott C, Rusch V, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from Intergroup trial 0139 (RTOG 93-09) [abstract no. 2497]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31–Jun 3; Chicago (IL). Proc Am Soc Clin Oncol 2003; 22: 621

    Google Scholar 

  40. Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000; 70: 1826–31

    Article  PubMed  CAS  Google Scholar 

  41. Voltolini L, Luzzi L, Ghiribelli C, et al. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy. Eur J Cardiothorac Surg 2001; 20: 1106–12

    Article  PubMed  CAS  Google Scholar 

  42. Detterbeck F, Ma S. Induction therapy and surgery for stage I–IIIA,B non-small lung cancer. In: Detterbeck F, Socinski M, Rivera M, et al., editors. Diagnosis and treatment of lung cancer. Philadelphia (PA): W.B. Saunders 2001: 267–82

    Google Scholar 

  43. Detterbeck FC, Socinski MA. Induction therapy and surgery for I–IIIA,B non-small cell lung cancer. In: Detterbeck FC, Socinski MA, Rivera MC, et al., editors. Diagnosis and treatment of lung cancer: an evidence-based guide for the practising clinician. Philadelphia (PA): W.B. Saunders Company, 2001: 267–82

    Google Scholar 

  44. Van Schil P, van der Schoot J, Poniewierski J, et al. Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. Lung Cancer 2002; 37: 281–5

    Article  PubMed  Google Scholar 

  45. Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, et al. Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2000; 70: 391–5

    Article  PubMed  CAS  Google Scholar 

  46. De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopyproven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006; 24: 3333–9

    Article  PubMed  Google Scholar 

  47. Solomon B, Mitchell JD, Bunn PA. Adjuvant chemotherapy for resected non-small cell lung cancer. Oncology 2005; 19: 1685–97

    PubMed  Google Scholar 

  48. Fleck CJ, Camargo K, Godoy D, et al. Chemoradiation therapy (CRT) versus chemotherapy (CT) alone as neo-adjuvant treatment for stage III non-small cell lung cancer (NSCLC): preliminary report of a phase III prospective randomized trial [abstract 1108]. Proc Am Soc Clin Oncol 1993; 12: 333

    Google Scholar 

  49. Sauvaget RJ-L, Rebischung J, Vannetzel J-M, et al. Phase III study of neo-adjuvant MVP versus MVP plus chemoradiotherapy in stage III disease [abstract]. Proc Am Soc Clin Oncol 2000; 19: a1935

    Google Scholar 

  50. Ruebe C, Riesenbeck D, Semik M, et al. Neoadjuvant chemotherapy followed by preoperative radiochemotherapy plus surgery or surgery plus post-operative radiotherapy in stage III non-small cell lung cancer: results of a randomized phase III trial of the German Lung Cancer Cooperative Group [abstract]. Int J Radiat Oncol Biol Phys 2004; 60: S130

    Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, 3009 Old Clinic Building CB 7305, Chapel Hill, North Carolina, 27599-7305, USA

    Thomas E. Stinchcombe & Mark A. Socinski

Authors
  1. Thomas E. Stinchcombe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark A. Socinski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas E. Stinchcombe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stinchcombe, T.E., Socinski, M.A. The Role of Induction Therapy for Resectable Non-Small Cell Lung Cancer. Drugs 67, 321–332 (2007). https://doi.org/10.2165/00003495-200767030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767030-00001

Keywords

Search

Navigation